<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668692</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1128</org_study_id>
    <nct_id>NCT02668692</nct_id>
  </id_info>
  <brief_title>LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis</brief_title>
  <official_title>Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMIC Co, Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment&#xD;
      of psoriasis in Japanese subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 3, national, multi-centre, 4-week, prospective, randomised, controlled,&#xD;
      parallel-group, open trial of LEO 80185 gel versus Dovobet® ointment in Japanese subjects&#xD;
      with psoriasis vulgaris.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp</measure>
    <time_frame>End of Week 4</time_frame>
    <description>'Overall improvement' for the target lesion on the scalp, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion.&#xD;
'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With 'Overall Improvement' for the Target Lesion on the Non-scalp Area of the Body</measure>
    <time_frame>End of Week 4</time_frame>
    <description>'Overall Improvement' for the target lesion on the non-scalp area of the body, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion.&#xD;
'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in the Sum of the Scores (Total Sign Score) for the Severity of the 3 Clinical Signs:Thickness, Scaliness, Redness From Baseline to End of Week 4 (Visit 1-4) for Each Target Lesion.</measure>
    <time_frame>From Baseline to end of Week 4 (Visit 1-4)</time_frame>
    <description>Severity was recorded for each of the 3 clinical signs according to the 9-point scales* below.&#xD;
*intermediate intervals (0.5, 1.5, 2.5, 3.5) serve as mid points between the defined grades.&#xD;
Redness 0=none (no erythema)&#xD;
slight (faint erythema, pink to very light red)&#xD;
mild (definite light red erythema)&#xD;
moderate (dark red erythema)&#xD;
severe (very dark red erythema)&#xD;
Thickness 0=none (no plaque elevation)&#xD;
slight (slight, barely perceptible elevation)&#xD;
mild (definite elevation but not thick)&#xD;
moderate (definite elevation, thick plaque with sharp edge)&#xD;
severe (very thick plaque with sharp edge)&#xD;
Scaliness 0=none (no scaling)&#xD;
slight (sparse, fine scale, lesions only partially covered)&#xD;
mild (coarser scales, most of lesions covered)&#xD;
moderate (entire lesion covered with coarse scales)&#xD;
severe (very thick coarse scales, possibly fissured)&#xD;
Negative change denotes a decrease in the score and therefore a decrease in disease severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80185 gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dovobet ® ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185 gel</intervention_name>
    <description>calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
    <arm_group_label>LEO 80185 gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dovobet ® ointment</intervention_name>
    <description>calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
    <arm_group_label>Dovobet ® ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Informed consent has been obtained.&#xD;
&#xD;
          -  2. Japanese subjects&#xD;
&#xD;
          -  3. Aged 20 years or above&#xD;
&#xD;
          -  4. Clinical diagnosis of psoriasis vulgaris amenable to topical treatment of less than&#xD;
             or equal to 30% BSA&#xD;
&#xD;
          -  5. A target psoriasis lesion on the scalp and on the non-scalp area of the body, each&#xD;
             lesion of a minimum size of 10 cm2 and scoring at least 2 (mild) for each of the&#xD;
             clinical signs (redness, thickness and scaliness).&#xD;
&#xD;
          -  6. Females of childbearing potential must have a negative result for a urine pregnancy&#xD;
             test at Day 1 (Visit 1) and must agree to use an adequate method of birth control.&#xD;
&#xD;
          -  7. Able to communicate with the (sub)investigator and understand and comply with the&#xD;
             requirements of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Systemic use of biological treatments with a potential effect on psoriasis vulgaris&#xD;
&#xD;
          -  2. Systemic treatments with all therapies other than biological treatments with a&#xD;
             potential effect on psoriasis vulgaris&#xD;
&#xD;
          -  3. PUVA therapy, UVB therapy or UVA therapy&#xD;
&#xD;
          -  4. Topical treatment of psoriasis on the areas to be treated with trial medication&#xD;
&#xD;
          -  5. Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D&#xD;
             analogues, potent or very potent corticosteroids or immunosuppressants&#xD;
&#xD;
          -  6. Topical treatment of conditions other than psoriasis with vitamin D analogues,&#xD;
             potent or very potent corticosteroids or immunosuppressants&#xD;
&#xD;
          -  7. Planned initiation of, or changes in, concomitant medication that may affect&#xD;
             psoriasis vulgaris&#xD;
&#xD;
          -  8. Patients with any of the following disorders (a) or symptoms (b) present on the&#xD;
             areas to be treated with trial medication: (a) viral (e.g., herpes or varicella)&#xD;
             lesions of the skin, fungal, spirochetal or bacterial skin infections, parasitic&#xD;
             infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne&#xD;
             vulgaris, atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns,&#xD;
             frostbite, wounds, animal skin disease (scabies, crabs, lice, etc.) or (b) fragility&#xD;
             of skin veins.&#xD;
&#xD;
          -  9. Other inflammatory skin diseases that may confound the evaluation of psoriasis&#xD;
             vulgaris.&#xD;
&#xD;
          -  10. Erythrodermic, exfoliative or pustular psoriasis&#xD;
&#xD;
          -  11. Planned excessive exposure of areas to be treated with trial medication to either&#xD;
             natural or artificial sunlight&#xD;
&#xD;
          -  12. Known or suspected disorders of calcium metabolism associated with hypercalcaemia,&#xD;
             or albumin-corrected serum calcium above the reference range&#xD;
&#xD;
          -  13. Known or suspected severe renal insufficiency, severe hepatic disorders or severe&#xD;
             heart disease.&#xD;
&#xD;
          -  14. Known or suspected hypersensitivity to any components of the investigational&#xD;
             products.&#xD;
&#xD;
          -  15. Clinical signs or symptoms of Cushing's disease or Addison's disease&#xD;
&#xD;
          -  16. Treatment with any non-marketed drug substance&#xD;
&#xD;
          -  17. Current participation in any other interventional clinical trial&#xD;
&#xD;
          -  18. Previously randomised in this trial&#xD;
&#xD;
          -  19. Females who are pregnant, wishing to become pregnant or are breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidemi Nakagawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Corporation Bikyukai Kokubu Dermatology</name>
      <address>
        <city>Kitami-shi</city>
        <state>Hokkaido</state>
        <zip>090-0832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <results_first_submitted>June 23, 2017</results_first_submitted>
  <results_first_submitted_qc>July 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2021</results_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEO 80185 gel, calcipotriol, betamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The trial had 213 participants enrolled and 206 participants randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 80185 Gel</title>
          <description>LEO 80185 gel: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
        </group>
        <group group_id="P2">
          <title>Dovobet® Ointment</title>
          <description>Dovobet® ointment: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 80185 Gel</title>
          <description>LEO 80185 gel: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
        </group>
        <group group_id="B2">
          <title>Dovobet® Ointment</title>
          <description>Dovobet® ointment: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="13.7"/>
                    <measurement group_id="B2" value="54.3" spread="14.2"/>
                    <measurement group_id="B3" value="52.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp</title>
        <description>'Overall improvement' for the target lesion on the scalp, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion.&#xD;
'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
        <time_frame>End of Week 4</time_frame>
        <population>All 206 randomised subjects are included in the full analysis set (FAS): 101 in the LEO 80185 group and 105 in the Dovobet® group.&#xD;
The per protocol analysis set (PPAS) was defined by excluding subjects from the FAS based on a review of protocol deviations. PPAS includes 94 subjects in the LEO 80185 group and 100 in the Dovobet® group.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185 Gel</title>
            <description>LEO 80185 gel: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
          </group>
          <group group_id="O2">
            <title>Dovobet® Ointment</title>
            <description>Dovobet® ointment: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp</title>
          <description>'Overall improvement' for the target lesion on the scalp, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion.&#xD;
'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
          <population>All 206 randomised subjects are included in the full analysis set (FAS): 101 in the LEO 80185 group and 105 in the Dovobet® group.&#xD;
The per protocol analysis set (PPAS) was defined by excluding subjects from the FAS based on a review of protocol deviations. PPAS includes 94 subjects in the LEO 80185 group and 100 in the Dovobet® group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Overall improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not overall improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the FAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.68</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>10.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the PPAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.68</p_value>
            <p_value_desc>Treatment comparison by Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>10.72</ci_upper_limit>
            <estimate_desc>Odds of 'overall improvement' in LEO 80185 gel group relative to Dovobet® ointment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With 'Overall Improvement' for the Target Lesion on the Non-scalp Area of the Body</title>
        <description>'Overall Improvement' for the target lesion on the non-scalp area of the body, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion.&#xD;
'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
        <time_frame>End of Week 4</time_frame>
        <population>All 206 randomised subjects are included in the full analysis set (FAS): 101 in the LEO 80185 group and 105 in the Dovobet® group.&#xD;
The per protocol analysis set (PPAS) was defined by excluding subjects from the FAS based on a review of protocol deviations. PPAS includes 94 subjects in the LEO 80185 group and 100 in the Dovobet® group.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185 Gel</title>
            <description>LEO 80185 gel: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
          </group>
          <group group_id="O2">
            <title>Dovobet® Ointment</title>
            <description>Dovobet® ointment: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With 'Overall Improvement' for the Target Lesion on the Non-scalp Area of the Body</title>
          <description>'Overall Improvement' for the target lesion on the non-scalp area of the body, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion.&#xD;
'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
          <population>All 206 randomised subjects are included in the full analysis set (FAS): 101 in the LEO 80185 group and 105 in the Dovobet® group.&#xD;
The per protocol analysis set (PPAS) was defined by excluding subjects from the FAS based on a review of protocol deviations. PPAS includes 94 subjects in the LEO 80185 group and 100 in the Dovobet® group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Overall improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not overall improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for the FAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.009</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the PPAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.003</p_value>
            <p_value_desc>Treatment comparison by Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>Odds of 'overall improvement' in LEO 80185 gel group relative to Dovobet® ointment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in the Sum of the Scores (Total Sign Score) for the Severity of the 3 Clinical Signs:Thickness, Scaliness, Redness From Baseline to End of Week 4 (Visit 1-4) for Each Target Lesion.</title>
        <description>Severity was recorded for each of the 3 clinical signs according to the 9-point scales* below.&#xD;
*intermediate intervals (0.5, 1.5, 2.5, 3.5) serve as mid points between the defined grades.&#xD;
Redness 0=none (no erythema)&#xD;
slight (faint erythema, pink to very light red)&#xD;
mild (definite light red erythema)&#xD;
moderate (dark red erythema)&#xD;
severe (very dark red erythema)&#xD;
Thickness 0=none (no plaque elevation)&#xD;
slight (slight, barely perceptible elevation)&#xD;
mild (definite elevation but not thick)&#xD;
moderate (definite elevation, thick plaque with sharp edge)&#xD;
severe (very thick plaque with sharp edge)&#xD;
Scaliness 0=none (no scaling)&#xD;
slight (sparse, fine scale, lesions only partially covered)&#xD;
mild (coarser scales, most of lesions covered)&#xD;
moderate (entire lesion covered with coarse scales)&#xD;
severe (very thick coarse scales, possibly fissured)&#xD;
Negative change denotes a decrease in the score and therefore a decrease in disease severity.</description>
        <time_frame>From Baseline to end of Week 4 (Visit 1-4)</time_frame>
        <population>The per protocol analysis set (PPAS) was defined by excluding subjects from the full analysis set (FAS) based on a review of protocol deviations. PPAS includes 94 subjects in the LEO 80185 group and 100 in the Dovobet® group.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185 Gel</title>
            <description>LEO 80185 gel: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
          </group>
          <group group_id="O2">
            <title>Dovobet® Ointment</title>
            <description>Dovobet® ointment: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in the Sum of the Scores (Total Sign Score) for the Severity of the 3 Clinical Signs:Thickness, Scaliness, Redness From Baseline to End of Week 4 (Visit 1-4) for Each Target Lesion.</title>
          <description>Severity was recorded for each of the 3 clinical signs according to the 9-point scales* below.&#xD;
*intermediate intervals (0.5, 1.5, 2.5, 3.5) serve as mid points between the defined grades.&#xD;
Redness 0=none (no erythema)&#xD;
slight (faint erythema, pink to very light red)&#xD;
mild (definite light red erythema)&#xD;
moderate (dark red erythema)&#xD;
severe (very dark red erythema)&#xD;
Thickness 0=none (no plaque elevation)&#xD;
slight (slight, barely perceptible elevation)&#xD;
mild (definite elevation but not thick)&#xD;
moderate (definite elevation, thick plaque with sharp edge)&#xD;
severe (very thick plaque with sharp edge)&#xD;
Scaliness 0=none (no scaling)&#xD;
slight (sparse, fine scale, lesions only partially covered)&#xD;
mild (coarser scales, most of lesions covered)&#xD;
moderate (entire lesion covered with coarse scales)&#xD;
severe (very thick coarse scales, possibly fissured)&#xD;
Negative change denotes a decrease in the score and therefore a decrease in disease severity.</description>
          <population>The per protocol analysis set (PPAS) was defined by excluding subjects from the full analysis set (FAS) based on a review of protocol deviations. PPAS includes 94 subjects in the LEO 80185 group and 100 in the Dovobet® group.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scalp (PPAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.43" spread="1.91"/>
                    <measurement group_id="O2" value="-6.79" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-scalp (PPAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" spread="2.44"/>
                    <measurement group_id="O2" value="-6.46" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of Informed Consent Form up to 14 days after last visit (Week 4).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LEO 80185 Gel</title>
          <description>LEO 80185 gel: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
        </group>
        <group group_id="E2">
          <title>Dovobet® Ointment</title>
          <description>Dovobet® ointment: calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Kaposi's varicelliform eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

